Hadasit Bio-Holdings

Press Releases

ProtAb and Enlivex receive CLAs

Dec. 24, 2012

Link to Hebrew immediate report

ProtAb and Enlivex have received the following convertible Loan agreements (CLAs)

Hadasit Bio Holdings will provide 1 million NIS in 4 installments to support Enlivex’s efforts in strengthening the company’s IP, attaining orphan drug status in Europe and the US, FDA approval of the companies phase II plans and preparations for its initiation.

Hadasit Bio Holdings and its partners (Clal Bio-Technolgy Industries and Pontifax) will provide $145,000 each to support research of the mechanism of action of ProtAb’s antibody and its preparation for clinical trials.

The terms of the loans are similar to the Company’s usual terms when providing loans to portfolio companies.

 
 

Press Releases Archive